You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

CLINICAL TRIALS PROFILE FOR LURBINECTEDIN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for LURBINECTEDIN

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01314599 ↗	Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome	Completed	PharmaMar	Phase 1	2011-05-01	Phase I Study of PM01183 in Patients with Advanced Acute Leukemia to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183.
NCT01831089 ↗	Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	Completed	PharmaMar	Phase 1	2013-09-01	Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
NCT01951157 ↗	A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients	Completed	PharmaMar	Phase 2	2013-09-11	A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients
NCT01980667 ↗	Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors	Completed	PharmaMar	Phase 1	2014-07-30	Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Cisplatin in Patients with Advanced Solid Tumors to determine the recommended dose (RD) of PM01183 in combination with cisplatin, to characterize the safety profile, the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity and to conduct an exploratory pharmacogenomic (PGx) analysis.
NCT02210364 ↗	Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).	Completed	PharmaMar	Phase 1	2013-04-01	Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination with Capecitabine in Patients with Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC) to determine the recommended dose (RD) of PM01183 in combination with capecitabine, to characterize the safety profile, to explore the feasibility of PM01183 dose optimization, to characterize the pharmacokinetics (PK), to obtain preliminary information on the clinical antitumor activity of this combination and to conduct an exploratory pharmacogenomic (PGx) analysis.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for LURBINECTEDIN

Condition Name

Chart
Table

Condition Name for LURBINECTEDIN
Intervention	Trials
Small-cell Lung Cancer	5
Advanced Solid Tumor	5
Ovarian Cancer	4
Advanced Solid Tumors	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for LURBINECTEDIN
Intervention	Trials
Lung Neoplasms	12
Small Cell Lung Carcinoma	11
Neoplasms	7
Sarcoma	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for LURBINECTEDIN

Trials by Country

Map
Table

Trials by Country for LURBINECTEDIN
Location	Trials
United States	90
Spain	24
Italy	12
United Kingdom	7
France	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for LURBINECTEDIN
Location	Trials
Massachusetts	9
Texas	8
California	7
Pennsylvania	6
New York	5
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for LURBINECTEDIN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for LURBINECTEDIN
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	1
Phase 2	11
[disabled in preview]	19
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for LURBINECTEDIN
Clinical Trial Phase	Trials
Not yet recruiting	15
Completed	10
Recruiting	9
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LURBINECTEDIN

Sponsor Name

Chart
Table

Sponsor Name for LURBINECTEDIN
Sponsor	Trials
PharmaMar	19
Jazz Pharmaceuticals	9
National Cancer Institute (NCI)	3
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for LURBINECTEDIN
Sponsor	Trials
Industry	36
Other	19
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.